MedTrace Logo

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

NCT05036434 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-23

No results posted yet for this study

Summary

* Clinical Indication : Advanced adrenal cortical carcinoma after platinum-based chemotherapy
* Trial Type : Single arm, prospective trial
* Route of administration : Intravenous (pembrolizumab) and peroral (lenvatinib)
* Treatment Groups : Single arm
* Number of trial participants : 30

Conditions

  • Adrenocortical Carcinoma

Interventions

DRUG

Pembrolizumab / Lenvatinib

Pembrolizumab Plus Lenvatinib administration.

Sponsors & Collaborators

  • MSD Korea Ltd.

    collaborator INDUSTRY

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Tak Yun · National Cancer Center, Republic of Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-15
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05036434 on ClinicalTrials.gov